FDA Enforcement Database

Drug Safety & Recalls Center

Access structured drug recall and safety information sourced directly from the U.S. Food & Drug Administration (FDA) OpenFDA Enforcement API. Stay informed on active market withdrawals, manufacturing defect notices, and drug safety advisories.

Last Synchronized
2 weeks ago
Total FDA Recalls
999
Active / Ongoing
962
Critical (Class I)
45
Data Provenance & Source Transparency: All drug recall records displayed are retrieved directly from the official U.S. FDA OpenFDA Enforcement API. Questo organizes and presents this data for medical education and research without modifying original regulatory facts. Explore OpenFDA API Documentation →
Medical & Legal Disclaimer: The information on this page is compiled for informational and educational reference only and does not constitute medical advice or clinical diagnosis. Never discontinue, start, or substitute any medication without consulting your prescribing doctor or a licensed pharmacist. For urgent health concerns regarding a recalled product, contact your physician immediately or report adverse events to FDA MedWatch.
Showing 801–820 of 999 factual FDA recall reports
Class II (Moderate Risk)
Drug recall Recall #: D-0580-2025

DULOXETINE

Manufacturer / Recalling Firm: Breckenridge Pharmaceutical, Inc.
Reason for Recall: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
FDA Report: Aug 20, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
Duloxetine Delayed-Release Capsules, USP, 60 mg, 1,000 Capsules per bottle, Rx Only, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain. Manufactured for: Quallent Pharmaceuticals Health LLC, Grand Cayman, Cayman Islands. NDC 82009-032-10
Lots / Batch Codes & Expiration Dates
Lot 240539C, Exp 1/31/2027
Distribution Scope
NJ, AZ, IN
Class II (Moderate Risk)
Drug recall Recall #: D-0578-2025

CARVEDILOL

Manufacturer / Recalling Firm: Glenmark Pharmaceuticals Inc., USA
Reason for Recall: CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.
FDA Report: Aug 20, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
Carvedilol Tablets, USP, 12.5 mg, 500-count bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd, Colvale-Bardez, Goa, 403513, India. Manufactured for Glenmark Pharmaceuticals, Inc., USA, Mahwah, NJ 07430. NDC 68462-164-05
Lots / Batch Codes & Expiration Dates
Lot#:19243202, Exp: 7/31/2026.
Distribution Scope
Nationwide in the USA
Class II (Moderate Risk)
Drug recall Recall #: D-0586-2025

SODIUM CHLORIDE

Manufacturer / Recalling Firm: B BRAUN MEDICAL INC
Reason for Recall: Lack of Assurance of Sterility; potential for fluid leakage at one of the weld sites.
FDA Report: Aug 20, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
0.9% Sodium Chloride Injection USP, L 8000, 1000mL Excel Container, Rx Only, Sterile, nonpyrogenic, single dose container, B. Braun Medical Inc., Bethlehem, PA 18018, NDC 0264-7800-00.
Lots / Batch Codes & Expiration Dates
Lot #: J5C919, Exp. 08/31/2027
Distribution Scope
Nationwide in the US
Class II (Moderate Risk)
Drug recall Recall #: D-0568-2025

Duloxetine D/R

Manufacturer / Recalling Firm: Direct Rx
Reason for Recall: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
FDA Report: Aug 13, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
Duloxetine D/R, 30 mg, 30 Caps, RX Only, Packaged as a) 30-count bottle NDC 61919-0482-30, b) 60-count bottle, NDC 61919-0482-60, c) 90-count bottle, NDC 61919-0482-90; Packaged & Distributed by: Direct Rx, Dist. By Breckenridge Pharm., Inc., Berlin, CT 06037,
Lots / Batch Codes & Expiration Dates
Lot #: a) 15AU2420, 01JY2407, 04OC2411, Exp 01/31/2027; 12SE2418, 24OC2424, 20NO2416, Exp 03/31/2027; 21AU2313, 21JY2311, 05JY2313, Exp Date 01/31/2026 b) 13OC2310, 05SE2304, 04AU2306, 21JY2317, 12JY2306, Exp 01/31/2026; 11JY2416, 28JU2414, 19AU2412, 02AU2409, Exp 01/31/2027; 11SE2416, 24OC2425, Exp 03/31/2027; c) 23AU2317, 21AU2314, Exp 01/31/20...
Distribution Scope
Nationwide
Class II (Moderate Risk)
Drug recall Recall #: D-0559-2025

Tirzepatide + Niacinamide 13.2 mg + 1.0mg/0.5 mL Inj Sol

Manufacturer / Recalling Firm: AEQUITA PHARMACY
Reason for Recall: Lack of Processing Controls.
FDA Report: Aug 13, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
Tirzepatide + Niacinamide 13.2 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.
Lots / Batch Codes & Expiration Dates
All Lots within expiry.
Distribution Scope
MA
Class II (Moderate Risk)
Drug recall Recall #: D-0571-2025

XOLAIR

Manufacturer / Recalling Firm: Cardinal Health Inc.
Reason for Recall: CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.
FDA Report: Aug 13, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
Xolair (omalizumab injection), 150 mg/ml, 1 auto-injector, Rx only, Genentech, Inc, South San Francisco, CA 9408, NDC: 50242-215-55.
Lots / Batch Codes & Expiration Dates
Lot: 3617756, Expires: 12/31/2025.
Distribution Scope
Nationwide Within the U.S.
Class II (Moderate Risk)
Drug recall Recall #: D-0557-2025

Tirzepatide + Niacinamide 8.8 mg + 1.0mg/0.5 ml Inj Sol

Manufacturer / Recalling Firm: AEQUITA PHARMACY
Reason for Recall: Lack of Processing Controls.
FDA Report: Aug 13, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
Tirzepatide + Niacinamide 8.8 mg + 1.0mg/0.5 ml Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.
Lots / Batch Codes & Expiration Dates
All Lots within expiry.
Distribution Scope
MA
Class II (Moderate Risk)
Drug recall Recall #: D-0565-2025

Semaglutide + Cyanocobalamin 2.67 mg + 0.25mg/0.5 mL Inj Sol

Manufacturer / Recalling Firm: AEQUITA PHARMACY
Reason for Recall: Lack of Processing Controls.
FDA Report: Aug 13, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
Semaglutide + Cyanocobalamin 2.67 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.
Lots / Batch Codes & Expiration Dates
All Lots within expiry.
Distribution Scope
MA
Class II (Moderate Risk)
Drug recall Recall #: D-0556-2025

Tirzepatide + Niacinamide 6.6 mg + 1.0mg/0.5 mL Inj Sol

Manufacturer / Recalling Firm: AEQUITA PHARMACY
Reason for Recall: Lack of Processing Controls.
FDA Report: Aug 13, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
Tirzepatide + Niacinamide 6.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.
Lots / Batch Codes & Expiration Dates
All Lots within expiry.
Distribution Scope
MA
Class II (Moderate Risk)
Drug recall Recall #: D-0560-2025

Tirzepatide + Niacinamide 16.6 mg + 1.0mg/0.5 mL Inj Sol

Manufacturer / Recalling Firm: AEQUITA PHARMACY
Reason for Recall: Lack of Processing Controls.
FDA Report: Aug 13, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
Tirzepatide + Niacinamide 16.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 3 x 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.
Lots / Batch Codes & Expiration Dates
All Lots within expiry.
Distribution Scope
MA
Class II (Moderate Risk)
Drug recall Recall #: D-0572-2025

XOLAIR

Manufacturer / Recalling Firm: Cardinal Health Inc.
Reason for Recall: CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.
FDA Report: Aug 13, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
Xolair (omalizumab injection), 75 mg/0.5 ml, Rx only, Genentech, Inc., South San Francisco, CA 94080, NDC 50242-214-55
Lots / Batch Codes & Expiration Dates
Lot: 3630004, Expires: 10/31/2025.
Distribution Scope
Nationwide Within the U.S.
Class II (Moderate Risk)
Drug recall Recall #: D-0561-2025

Semaglutide + Cyanocobalamin 0.44 mg + 0.25mg/0.5 mL Inj Sol

Manufacturer / Recalling Firm: AEQUITA PHARMACY
Reason for Recall: Lack of Processing Controls.
FDA Report: Aug 13, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
Semaglutide + Cyanocobalamin 0.44 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.
Lots / Batch Codes & Expiration Dates
All Lots within expiry.
Distribution Scope
MA
Class II (Moderate Risk)
Drug recall Recall #: D-0566-2025

DOXEPIN HYDROCHLORIDE

Manufacturer / Recalling Firm: Alembic Pharmaceuticals Limited
Reason for Recall: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
FDA Report: Aug 13, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
Doxepin Hydrochloride Capsules, USP, 10 mg, 100 Capsules, Rx only, Manufactured by: Alembic Pharmaceuticals Limited, Panela v 389350, Gujarat, India, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, NDC 62332-637-31
Lots / Batch Codes & Expiration Dates
Lot: 2305015142, Exp. Date: 9/30/2025
Distribution Scope
Nationwide in the USA.
Class II (Moderate Risk)
Drug recall Recall #: D-0558-2025

Tirzepatide + Niacinamide 11.24 mg + 1.0mg/0.5 mL Inj Sol

Manufacturer / Recalling Firm: AEQUITA PHARMACY
Reason for Recall: Lack of Processing Controls.
FDA Report: Aug 13, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
Tirzepatide + Niacinamide 11.24 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.
Lots / Batch Codes & Expiration Dates
All Lots within expiry.
Distribution Scope
MA
Class II (Moderate Risk)
Drug recall Recall #: D-0573-2025

RECOMBINATE

Manufacturer / Recalling Firm: Cardinal Health Inc.
Reason for Recall: CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.
FDA Report: Aug 13, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
RECOMBINATE, [Antihemophilic Factor (Recombinant)], 5 mL vials, Rx Only, Takeda Pharmaceuticals USA, Cambridge, MA 02142, NDC: 00944-2843-01
Lots / Batch Codes & Expiration Dates
Lot: TRB23802AC, Expires: 03/18/2026; TRA22804AA, Expires: 10/18/2025
Distribution Scope
Nationwide Within the U.S.
Class II (Moderate Risk)
Drug recall Recall #: D-0554-2025

Tirzepatide + Niacinamide 2.2 mg + 1.0mg/0.5 mL Inj Sol

Manufacturer / Recalling Firm: AEQUITA PHARMACY
Reason for Recall: Lack of Processing Controls.
FDA Report: Aug 13, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
Tirzepatide + Niacinamide 2.2 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.
Lots / Batch Codes & Expiration Dates
All Lots within expiry
Distribution Scope
MA
Class II (Moderate Risk)
Drug recall Recall #: D-0574-2025

SPIRONOLACTONE

Manufacturer / Recalling Firm: SUN PHARMACEUTICAL INDUSTRIES INC
Reason for Recall: Presence of foreign substance: identified as aluminum.
FDA Report: Aug 13, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
Spironolactone Tablets, USP, 25 mg, 100-count bottle, Rx only, Mfg. by: Frontida BioPharm, Inc., 1100 Orthodox St, Philadelphia, PA 19124, Dist. by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, NDC 53489-143-01
Lots / Batch Codes & Expiration Dates
Lot # P3314, Exp 11/30/2026
Distribution Scope
USA Nationwide
Class II (Moderate Risk)
Drug recall Recall #: D-0553-2025

Semaglutide + Cyanocobalamin 0.22 mg + 0.25mg/0.5 ml Inj Sol

Manufacturer / Recalling Firm: AEQUITA PHARMACY
Reason for Recall: Lack of Processing Controls.
FDA Report: Aug 13, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
Semaglutide + Cyanocobalamin 0.22 mg + 0.25mg/0.5 ml Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.
Lots / Batch Codes & Expiration Dates
All Lots within expiry
Distribution Scope
MA
Class II (Moderate Risk)
Drug recall Recall #: D-0555-2025

Tirzepatide + Niacinamide 4.4 mg + 1.0mg/0.5 mL Inj Sol

Manufacturer / Recalling Firm: AEQUITA PHARMACY
Reason for Recall: Lack of Processing Controls.
FDA Report: Aug 13, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
Tirzepatide + Niacinamide 4.4 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.
Lots / Batch Codes & Expiration Dates
All Lots within expiry.
Distribution Scope
MA
Class II (Moderate Risk)
Drug recall Recall #: D-0562-2025

Semaglutide + Cyanocobalamin 0.88 mg + 0.25mg/0.5 mL Inj Sol

Manufacturer / Recalling Firm: AEQUITA PHARMACY
Reason for Recall: Lack of Processing Controls.
FDA Report: Aug 13, 2025 Status: Ongoing Voluntary: Firm initiated Source: FDA
View Full Report
Affected Product Description
Semaglutide + Cyanocobalamin 0.88 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.
Lots / Batch Codes & Expiration Dates
All Lots within expiry.
Distribution Scope
MA

FDA Recall Classes & Health Hazard Definitions

Official regulatory classifications defined by the U.S. Food & Drug Administration (21 CFR Part 7)

FDA Health Hazard Classifications
Class I — High Risk Severity

Class I Recall

Regulatory Definition: A situation in which there is a reasonable probability that exposure to a recalled product will cause serious adverse health consequences or death.

Examples: Microbial contamination of sterile injectables, presence of unlabelled severe allergens, toxic impurities, or dosage potency errors.
Class II — Moderate Risk Severity

Class II Recall

Regulatory Definition: A situation in which exposure to a recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse consequences is remote.

Examples: Sub-potent non-life-sustaining tablets, minor dissolution rate variations, or outer carton label misprints.
Class III — Low Risk Severity

Class III Recall

Regulatory Definition: A situation in which exposure to a recalled product is not likely to cause adverse health consequences, but violates FDA packaging or manufacturing regulations.

Examples: Minor packaging flaws, harmless tablet color variances, or minor typographical errors in package inserts.
Enforcement Action Statuses
Ongoing Action

Ongoing Status

The recall action is actively in progress across supply chains, distributors, healthcare facilities, and retail pharmacies nationwide.

Completed / Terminated

Completed & Terminated Status

The FDA has confirmed that all reasonable efforts have been made to remove or correct the product, and the enforcement file is officially closed.

System Notice

Confirm Action